Institute of Biomedical Research Corp MRES
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRES is a good fit for your portfolio.
News
-
MRES: M2Bio Food and Beverage Wraps Up 2023/ 2024 Looking Ahead
-
MRES: M2Bio Sciences Provides Corporate Update
-
MRES: M2Bio Sciences Introduces M2BioKids: A Pioneering Approach to Elevating Childhood Health and Development
-
MRES: M2Enviro 2023 Year-End Review and 2024 Looking Forward
-
MRES: M2Biome 2023 Year-End Review and 2024 Looking Forward
-
Real American Announces Acquisition of M2MMA from MRES
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.01–0.03
- Bid/Ask
- $0.01 / $0.01
- Market Cap
- $788,740.93
- Volume/Avg
- 77,389 / 829,650
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Institute of Biomedical Research Corp is a biomedical research and development company. The company is focused on alternative plant-based cannabinoids and mental health therapeutic research. The Institute has expanded its research to also include the augmentation of traditional medicine and the emerging science of medicinal mushrooms.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.m2bio.co
Valuation
|
Metric
|
MRES
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MRES
|
|---|---|
Quick Ratio | — |
Current Ratio | — |
Interest Coverage | −520.29 |
Quick Ratio
No chart available
Profitability
|
Metric
|
MRES
|
|---|---|
Return on Assets (Normalized) | −12,186.34% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −15,140.73% |
Return on Assets
No chart available
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Byjfcwxm | Qycdt | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mswtlkcw | Hlrhxz | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fnqbhcm | Qdxxsns | $97.8 Bil | |
MRNA
| Moderna Inc | Dssjbqhh | Mppgy | $41.3 Bil | |
ARGX
| argenx SE ADR | Mtnqpymsd | Vrff | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Knmrrlbh | Djmr | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vtyndvkh | Lcdbrv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Npyyxkx | Xswdw | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Njfvjjklr | Pvwxvgl | $12.5 Bil | |
INCY
| Incyte Corp | Hhcpgnpw | Qbyzg | $11.6 Bil |